ArticleEuropean journal of breast health2026
Clinical Outcomes in Initial Hirudotherapy versus Standard Treatment in Idiopathic Granulomatous Mastitis: A Comparative Cohort Study.
Article in European journal of breast health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Idiopathic granulomatous mastitis (IGM) is a chronic inflammatory disease characterized by a high risk of recurrence and fistula formation. Spontaneous remission has been reported in up to 50% of cases, particularly in mild forms, within 6-24 months without intervention, but inadequate management may allow disease progression. The aim of this study was to compare the clinical outcomes of patients who initially preferred hirudotherapy (leech therapy) with those managed with evidence-based stepwise conventional care. Materials and Methods: We retrospectively analyzed histopathologically confirmed IGM patients. Patients were divided into two groups: Group 1 who delayed conventional treatment for ≥6 months because they initially chose hirudotherapy, and Group 2 who received standardized stepwise management (steroids, aspiration, or surgery). Clinical outcomes included complete remission, overall recurrence/persistence, clinically significant (extensive/severe) recurrence, fistulizing/complicated recurrence, and the need for surgical intervention. Results: The study included 298 patients, with 41 (13.8%) in Group 1 and 257 (86.2%) in Group 2. Median delay to presentation was significantly longer in Group 1 (15 Conclusion: Initial exclusive reliance on hirudotherapy was associated with markedly lower remission rates, substantially higher rates of clinically significant recurrence, longer delays before medical evaluation, and increased surgical needs despite comparable baseline severity. These findings suggest that hirudotherapy alone does not appear to modify the immune-mediated course of IGM and may result in a higher proportion of refractory cases presenting to hospital settings, as milder cases in the community may resolve spontaneously without seeking care. Early adherence to standardized stepwise care may therefore be important to prevent progression to severe recurrence and reduce the need for surgery. However, further prospective studies are required to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.